Which laboratory tests and imaging should be ordered to evaluate a patient for polycystic ovary syndrome (PCOS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory and Imaging Workup for PCOS

All women being evaluated for PCOS should have TSH, prolactin, and 17-hydroxyprogesterone (17-OHP) measured to exclude mimicking disorders, along with assessment of androgen levels (total testosterone and sex hormone-binding globulin) and pelvic ultrasound to document polycystic ovarian morphology when needed to meet diagnostic criteria. 1

Essential Laboratory Tests

The diagnostic workup follows a structured approach based on the Rotterdam criteria, which requires meeting 2 of 3 features: androgen excess, ovulatory dysfunction, or polycystic ovaries 1.

Mandatory Screening Tests (All Patients)

These tests exclude conditions that mimic PCOS and must be performed in every patient:

  • TSH - excludes thyroid disease presenting with menstrual irregularity
  • Prolactin - excludes hyperprolactinemia (can present with amenorrhea or hirsutism)
  • 17-hydroxyprogesterone (17-OHP) - excludes nonclassic congenital adrenal hyperplasia (found in 1.5-6.8% of patients with androgen excess) 1

Androgen Assessment

When hyperandrogenism is not clinically obvious, measure:

  • Total testosterone
  • Sex hormone-binding globulin (SHBG) - allows calculation of free androgen index
  • Free or bioavailable testosterone (optional, enhances diagnostic accuracy) 2

Note that you do not need universal androgen screening if the patient already meets two diagnostic criteria clinically 1. However, recent evidence shows that standardizing the initial biochemical panel reduces diagnostic delays significantly - patients with comprehensive testing at first venepuncture had median time to diagnosis of 29 days versus 255 days for those requiring multiple testing episodes 3.

Additional Hormonal Tests

  • LH and FSH - While an LH/FSH ratio >2:1 occurs in 55% of PCOS patients 4, this is not required for diagnosis and has limited sensitivity and specificity 5
  • Anti-Müllerian hormone (AMH) - Not required for diagnosis per guidelines 1, but recent research demonstrates AMH alone has good diagnostic accuracy (AUROC 0.884), and combining AMH with ovarian volume improves performance (AUROC 0.906) 2

Imaging

Pelvic Ultrasound

Transvaginal ultrasound is the gold standard for documenting polycystic ovarian morphology, defined as:

  • At least one ovary with ≥12 follicles measuring 2-9 mm, OR
  • Ovarian volume >10 mL
  • In the absence of a dominant follicle >10 mm 1

Important caveats:

  • Ultrasound is NOT required if the patient already meets two diagnostic criteria clinically (hyperandrogenic chronic anovulation) 1
  • Total ovarian area >5.5 cm² is an alternative morphologic criterion 5
  • Recent data shows ovarian volume combined with AMH provides excellent diagnostic accuracy 2

Selective Additional Testing

For patients with atypical presentations, consider:

  • 24-hour urinary free cortisol - if Cushing's syndrome suspected (proximal muscle weakness, central obesity)
  • Dehydroepiandrosterone sulfate (DHEA-S) - if virilization present
  • IGF-1 - if acromegaly suspected (frontal bossing) 1

Metabolic Screening

While not required for diagnosis, assess metabolic risk:

  • Oral glucose tolerance test with insulin levels - evaluates insulin resistance
  • Lipid panel
  • Body mass index and waist-hip ratio 6

Practical Algorithm

  1. Document clinical features: menstrual irregularity pattern, hirsutism (Ferriman-Gallwey score), acne
  2. Order comprehensive initial panel (single venepuncture): TSH, prolactin, 17-OHP, total testosterone, SHBG, LH, FSH 3
  3. Perform pelvic ultrasound if needed to meet diagnostic criteria
  4. Add selective tests only for atypical presentations

Critical pitfall: Ordering incomplete initial testing leads to diagnostic delays of 6-8 months 3. The most efficient approach uses a standardized panel at first evaluation rather than sequential testing.

Related Questions

Which laboratory tests should be ordered in a fasting morning sample to evaluate for polycystic ovary syndrome?
Which laboratory tests should be ordered to exclude polycystic ovary syndrome (PCOS) in a reproductive‑age woman with menstrual irregularities or signs of hyperandrogenism?
What hormonal workup should be performed in a reproductive‑age woman with suspected polycystic ovary syndrome, and when should it be done relative to the menstrual cycle and contraceptive use?
In a patient 10 days after the end of her menstrual period, are low estradiol, normal follicle‑stimulating hormone (FSH), low progesterone, normal luteinizing hormone (LH), and normal testosterone levels consistent with a diagnosis of polycystic ovary syndrome (PCOS)?
In a woman with polycystic ovary syndrome, is a fasting cortisol level of 5.2 µg/dL within the normal range and does it require further evaluation for hypercortisolism?
Can prazosin help treat the paranoid delusions triggered by perceived laughter in a patient with schizoaffective disorder?
What are the appropriate renal dosing recommendations for meropenem, vancomycin, and clindamycin in a 60‑year‑old dialysis patient weighing 70 kg?
Are left atrial enlargement and left ventricular hypertrophy considered structural heart disease?
In a 10-year-old child with attention-deficit/hyperactivity disorder, is immediate-release methylphenidate (Ritalin) generally better tolerated than extended-release methylphenidate (Concerta)?
What are the long‑term risks of disease‑modifying anti‑rheumatic drugs (DMARDs) in adults with rheumatoid arthritis or similar inflammatory conditions?
In which clinical situations should gabapentin be preferred over pregabalin for neuropathic pain, and how do their dosing regimens and renal dose adjustments differ?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.